Clinical Characteristics and Outcomes of US Extensive Stage Small Cell Lung Cancer (ES-SCLC) Patients not Receiving Guideline Preferred Regimens
07:30am - 03:45pm EDT - April 1, 2023
07:30am - 03:45pm EDT - April 1, 2023
Author(s):
- Dr. Daniel Simmons, PharmD, MS, Director of Oncology Outcomes Research, AstraZeneca
Tags: Outcomes and Health Services Research
| Display Label | Action |
|---|---|
| ES-SCLC Guideline Concordance Poster NCCN 2023 Final.pdf | Download Handout |